(2-ethyl-1-oxobutoxy)methyl (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2-ethyl-1-oxobutoxy)methyl (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
• 英文别名: 4-Thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1R)-1-hydroxyethyl)-7-oxo-3-(((1R,3S)-tetrahydro-1-oxido-3-thienyl)thio)-, (2-ethyl-1-oxobutoxy)methyl ester, (5R,6S)-；2-ethylbutanoyloxymethyl (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
• 化学式: C₁₉H₂₇NO₇S₃
• 分子量: 477.624
• InChiKey: NBPVNGWRLGHULH-JKOUTOBWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  30
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  180
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  2-乙基丁酸 在 氯化亚砜 、 N,N-二异丙基乙胺 、 sodium iodide 、 zinc(II) chloride 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 23.0h， 生成 (2-ethyl-1-oxobutoxy)methyl (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
  参考文献：
  名称：

  PENEM PRODRUGS

  摘要：

  瑟洛佩内姆的口服可利用的前药，例如其溶剂和水合物，其制备、配方和用于治疗和预防哺乳动物（如人类）感染。本摘要不限于该发明。

  公开号：

  US20080009474A1

文献信息

• Penem prodrugs
  申请人：Pfizer, Inc.

  公开号：US07795243B2

  公开（公告）日：2010-09-14

  Orally bioavailable prodrugs of sulopenem, e.g., and solvates and hydrates thereof, preparation thereof, formulation thereof, and use to treat and prevent infection in mammals such as humans. This abstract is not limiting to the invention.

  口服可利用的舒洛匹南前药，例如其溶剂和水合物，其制备、配方和用于治疗和预防哺乳动物（例如人类）感染的用途。本摘要不限于该发明。
• Combinations of beta-lactam compounds and probenecid and uses thereof
  申请人：Iterum Therapeutics International Limited

  公开号：US11478428B2

  公开（公告）日：2022-10-25

  The present disclosure relates to bilayer tablets comprising a second layer comprising a β-lactam compound or a pharmaceutically acceptable salt thereof; and a first layer comprising probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the bilayer tablets.

  本公开涉及双层片剂，其第二层包括β-内酰胺化合物或其药学上可接受的盐；第一层包括丙磺舒或其药学上可接受的盐。本公开还涉及使用双层片剂治疗或预防疾病的方法。
• COMBINATIONS OF BETA-LACTAM COMPOUNDS AND PROBENECID AND USES THEREOF
  申请人：Iterum Therapeutics International Limited

  公开号：US20200253878A1

  公开（公告）日：2020-08-13

  The present disclosure relates to bilayer tablets comprising a second layer comprising a β-lactam compound or a pharmaceutically acceptable salt thereof; and a first layer comprising probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the bilayer tablets.
• COMBINATIONS OF BETA-LACTAM COMPOUNDS, PROBENECID, AND VALPROIC ACID AND USES THEREOF
  申请人：Iterum Therapeutics International Limited

  公开号：US20210283112A1

  公开（公告）日：2021-09-16

  The present disclosure relates to combinations of valproic acid or a pharmaceutically acceptable salt thereof, a β-lactam compound or a pharmaceutically acceptable salt thereof, and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the combinations.